Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
Intraday
Monitor top intraday performers in real time
ETF Screener
Get the best of Mutual Funds and flexibility of Stocks
IPO
Track upcoming and ongoing IPOs
MTFs
Buy now, pay later
Stock Screener
Filter based on RSI, PE ratio and more
Stock Events
Dividends, bonus, buybacks and more
Demat Account
Begin your stock market journey
Share Market Today
Live news updates from stock market
F&O
Trade in Futures & Options
Trade in F&O using the terminal. View charts, indicators, track your orders , P&L and watchlists in a single space
Indices
Track markets across the globe
Terminal
Track charts, orders, positions, watchlists in one place
Option chain
Analyse chains, view payoffs, create baskets
Pledge
Get extra balance for trading
Commodities
Trade in Crude Oil, Gold, Silver and more
API trading
Set up and execute trades through our API
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
Mutual Fund Houses
Know about AMCs, funds, fund managers
NFO’s
Track all active NFOs in one place
Mutual Funds by Groww
Mutual funds by Groww designed for your investment goals
Start SIP
Build long-term wealth through disciplined monthly investing.
Mutual Funds screener
Filter funds based on risk, fund size and more
Track Funds
Import funds and track all investments in a single place
Compare Funds
More
SIP calculator
Estimate returns on a SIP
Brokerage calculator
Estimate charges for your trade/investment
Margin calculator
Estimate balance needed to buy/sell a stock
SWP calculator
Returns on your systematic withdrawal plan
Pricing
Brokerage and charges on Groww
Blog
Create Alert
Watchlist
Biocon
Option Chain
₹387.95
0.00 (0.00%)
1D
Manage alerts
Active alerts for Biocon
ADD NEW ALERT
NSE
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Terminal
Create Stock SIP
Automate your investments in this
BSE .
8 hours ago
Biocon Ltd acquired OCRPS of Biocon Biosphere Ltd and Biocon Pharma Ltd. Acquisition supports subsidiaries' working capital, capex, and corporate needs; total cost Rs. 315.3 Cr.
ScoutQuest .
6 days ago
Biocon Biologics focuses on expansion and new drug launches. Shreehas Tambe discusses developments on ET Now.
ScoutQuest .
6 days ago
Biocon targets $1B GLP-1 liraglutide market in US and EU. CEO Siddharth Mittal highlights this strategic business move.
ScoutQuest .
1 week ago
Biocon Ltd shared an investor presentation on Feb 25-26, 2026, covering company overview and business segments. Focus on Biocon-Biocon Biologics integration, product portfolio, manufacturing, and global presence highlighted.
ScoutQuest .
1 week ago
Biocon receives US FDA approval for Liraglutide prefilled pens, aiding weight management. US GLP-1 weight loss drug market was $127M in Dec 2025, driven by obesity trends.
ScoutQuest .
2 weeks ago
Biocon Biologics anticipates robust FY27 growth due to rising biosimilar adoption.
Livesquawk .
2 weeks ago
HSBC maintains a buy rating on Biocon, revising target price to ₹445. Earlier target price was ₹455, now reduced by ₹10.
Livesquawk .
2 weeks ago
Biocon expects INR 300 Cr interest savings from FY27 by clearing structured debt. Net debt is $1.1B-$1.2B with a debt-to-EBITDA ratio below 2.5x; CRDMO optimistic on growth.
Livesquawk .
2 weeks ago
Biocon targets steady growth, better margins, and cash flow-driven value creation. It expects biosimilar growth next fiscal, with current margins around mid-20s.
Moneycontrol .
2 weeks ago
Biocon targets high double-digit revenue growth with global rollout of generic obesity drugs, including liraglutide and Wegovy. Biocon plans U.S. launch in FY24 and Canada in 2024; cautious about early India entry due to price competition and trial costs.